[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100419099":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":21,"locations":29,"responsibleParty":55,"collaborators":7,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":7,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":7,"briefSummary":73,"conditions":74,"keywords":7,"overallStatus":32,"whyStopped":7,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Heart Center Leipzig - University Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","ECG, Echo, laboratory tests, CMR, PET-CT, Biopsy","ECG - 12 leads ECG Echo: transthoracic echocardiography laboratory tests: full blood count, electrolytes, creatinine, high sensitive cardiac troponin T, angiontesin converting enzyme, soluble interleukin-2 receptor, cardiac magnetic resonance imaging: 1.5 Tesla scanner, Conventional cine imaging and late gadolinium enhancement imaging PET-CT: 18F-fluorodeoxyglucose (FDG)- positron emission tomograph Biopsy: cardiac biopsy = endomyocardial biopsy, left and right ventricle, at least 5 specimens in formaldehyd and 3 specimens for testing of infectious agents Biopsy: extracardiac biopsy, as accessible according to imaging",[14,18],{"name":15,"affiliation":16,"role":17},"Borislav Dinov, MD","Heart Center Leipzig - University Hospital, Department Electrophysiology","PRINCIPAL_INVESTIGATOR",{"name":19,"affiliation":16,"role":20},"Laura Ueberham, MD","STUDY_CHAIR",[22,26],{"name":15,"role":23,"phone":24,"phoneExt":7,"email":25},"CONTACT","+49 341 865 1431","borislav.dinov@helios-gesundheit.de",{"name":19,"role":23,"phone":27,"phoneExt":7,"email":28},"+49341 865 1431","laura.ueberham@helios-gesundheit.de",[30],{"facility":31,"status":32,"city":33,"state":7,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Heart Center of Leipzig","RECRUITING","Leipzig","04289","Germany","DE",{"type":38,"coordinates":39},"Point",[40,41],12.37129,51.33962,{"lat":41,"lon":40},[44,48,52],{"name":45,"role":23,"phone":46,"phoneExt":7,"email":47},"Borislav Dinov, PhD","+49341865252134","Borislav.Dinov@helios-gesundheit.de",{"name":49,"role":23,"phone":50,"phoneExt":7,"email":51},"Hans Ebbinghaus, MD","+49341865252550","Hans.Ebbinghaus@helios-gesundheit.de",{"name":53,"role":54,"phone":7,"phoneExt":7,"email":7},"Laura Ueberham","SUB_INVESTIGATOR",{"type":17,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Borislav Dinov","Head of Ventricular Tachycardia Unit","100419099","diagnostic-criteria-in-cardiac-sarcoidosis-100419099",false,"NCT04737317","Diagnostic Criteria in Cardiac Sarcoidosis","Evaluation of Diagnostic Criteria in Cardiac Sarcoidosis - an Observational Study","ELDORADO","Inclusion Criteria:\n\n* patients with suspected CS due to the following presentations:\n\n  1. age \\\u003C 65 years and new higher degree AV block, causative coronary artery disease excluded\n  2. age \\\u003C 65 years and new ventricular tachycardia, causative coronary artery disease excluded\n  3. age \\\u003C 65 years and ventricular tachycardia, causative coronary artery disease excluded\n  4. extracardiac sarcoidosis and cardiac involvement suggested (palpitations, abnormal ECG, abnormal echocardiography)\n\nTo diagnose CS one of the following diagnostic tools will be used:\n\nA) World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG)\n\nB) Heart Rhythm Society expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis\n\nC) Japanese Society of Nuclear Cardiology (JSNC)\n\nPatients whit histological confirmation from myocardial tissue fullfil will be defined as proven CS. (Group 1)\n\nPatients with clinical and imaging findings highly suggesting CS, but without histological confirmation from myocardial biopsy will be defined as probable CS (Group 2)\n\nPatients who do not fullfil the criteria or exhibiting findings suggesting an alternative, more likely diagnosis, will be considered as unlikely CS (Group 3)\n\nExclusion Criteria:\n\n* unable or unwilling to provide informed consent\n* patients who are pregnant or lactating\n* noncompliant patients refusing the recommended therapy\n* age \\\u003C 18 years","ALL","18 Years",{"count":69,"type":70},100,"ESTIMATED","2 Years","OBSERVATIONAL","The purpose of the study is to evaluate the accuracy of the current diagnostic criteria of cardiac sarcoidosis.",[75],"Cardiac Sarcoidosis","2023-05-08",{"date":78,"type":79},"2023-05-09","ACTUAL",{"date":81,"type":79},"2023-05-01",{"date":83,"type":70},"2027-01-01",{"name":5,"class":6},1]